RESUMO

The advancement of next-generation sequencing has enabled the identification of specific mutations associated with early infantile epileptic encephalopathies (EIEEs). In EIEE, epileptic spasms and seizures that occur since early childhood lead to impaired neurological development. The CYFIP2 p.Arg87Cys variant was recently related to EIEE. CYFIP2 participates in the Wave Regulatory Complex (WRC), which is related to the regulation of actin dynamics. The variant residue is at the interface between the CYFIP2 protein and WAVE1 protein inside the WRC. Thus, the weakening of this interaction induced by the residue modification, which also causes the flexibilization of the loop 80-110 within the CYFIP2 structure, allows the constant activation of the WCR. This study aimed to identify ligands for CYFIP2 p.Arg87Cys and potential therapy targets using in silico in vitro approaches. Models of different CYFIP2 versions were constructed, and molecular docking analyses were conducted. A total of 3946 ligands from the PDE3 and Drugbank databases were screened, leading to the identification of 11 compounds that selectively bind to the variant protein. The impact of binding in CYFIP2 was also evaluated using a thermal stability assay. These findings contribute to a better understanding of CYFIP2's functional role in pathology and can guide more in vitro experiments, facilitating the development of targeted therapies for CYFIP2-related conditions.

RESUMO

OBJECTIVE: Variants in the ATP1A2 gene exhibit a wide clinical spectrum, ranging from familial hemiplegic migraine to childhood epilepsies and early infantile developmental epileptic encephalopathy (EIDEE) with movement disorders. This study aims to describe the epileptology of three unpublished cases and summarize epilepsy features of the other 17 published cases with ATP1A2 variants and EIDEE. METHODS: Medical records of three novel patients with pathogenic ATP1A2 variants were retrospectively reviewed. Additionally, the PUBMED, EMBASE, and Cochrane databases were searched until December 2023 for articles on EIDEE with ATP1A2 variants, without language or publication year restrictions. RESULTS: Three female patients, aged 6 months-10 years, were investigated. Epilepsy onset occurred between 5 days and 2 years, accompanied by severe developmental delay, intellectual disability, drug-resistant epilepsy, severe movement disorder, and recurrent status epilepticus. All individuals had pathogenic variants of the ATP1A2 gene (ATP1A2 c.720_721del (p.Ile240MetfsTer9), ATP1A2c.3022C > T (p.Arg1008Trp), ATP1A2 c.1096G > T (p.Gly366Cys), according to ACMG criteria. Memantine was p) rescribed to three patients, one with a reduction in ictal frequency, one with improvement in gait pattern, coordination, and attention span, and another one in alertness without significant side effects. SIGNIFICANCE: This study reinforces the association between ATP1A2 variants and a severe phenotype. All patients had de novo variants, focal motor seizures with impaired awareness as the primary type of seizure; of the 11 EEGs recorded, 10 presented a slow background rhythm, 7 multifocal interictal epileptiform discharges (IED), predominantly temporal IEDs, followed by frontal IED, as well as ten ictal recordings, which showed ictal onset from the same regions mentioned above. Treatment with antiseizure medication was generally ineffective, but memantine showed moderate improvement. Prospective studies are needed to enlarge the phenotype and assess the efficacy of NMDA receptor antagonist therapies in reducing seizure frequency and improving quality of life.

Assuntos

RESUMO

OBJECTIVE: There is growing evidence that ketogenic dietary therapy (KDT) can be safely and efficiently used in young children, but little evidence exists on its use in newborns. Developmental and epileptic encephalopathies starting in the neonatal period or early infancy usually present a poor prognosis. The aim of this study was to evaluate effectiveness, safety, and survival of infants younger than 3 months of age with drug-resistant epilepsy in whom KDT was used. METHODS: A retrospective study was conducted to evaluate neonates and infants younger than 3 months who started KDT for drug-resistant developmental and epileptic encephalopathies at three referral centers. Data were collected on demographic features, time of epilepsy onset, epilepsy syndrome, seizure type, seizure frequency at diet onset, etiology, details regarding diet initiation, type of ketogenic formula, breastfeeding, route of administration, blood ketones, growth, length of NICU stay, and survival. RESULTS: Nineteen infants younger than 12 weeks of life who received KDT with a minimum follow-up of 1 month were included; 13 had early-infantile developmental and epileptic encephalopathy, four epilepsy of infancy with migrating focal seizures, and two focal epilepsy. A >50% response was observed in 73.7% at 1 month on the diet; 37% achieved a > 75% seizure reduction, and 10.5% became seizure free. At 3 months, a >50% decrease in seizure frequency was observed in 72.2%; 15.8% had a >75% reduction; 21% became seizure free. Overall survival was 76% at 1 year on diet. Incidence of acute and late adverse effects was low and most adverse effects were asymptomatic and manageable. SIGNIFICANCE: Our experience suggests that KDT is safe and effective in newborns and very young infants; however, further studies on the management of the diet in this vulnerable age group are necessary.

Assuntos

RESUMO

The identification of factors that affect cannabidiol (CBD) systemic exposure may aid in optimizing treatment efficacy and safety in clinical practice. In this study, we aimed to correlate CBD plasma concentrations at a steady state to demographic, clinical, and pharmacological characteristics as well as seizure frequency after the administration of a purified CBD oil solution in a real-world setting of children with drug-resistant developmental and epileptic encephalopathies (DEEs). Patients receiving oral CBD pharmaceutical products at maintenance were enrolled. Venous blood samples were drawn before the CBD morning dose, 12 h apart from the last evening dose (C0 or CBD trough concentration). A linear mixed-effect analysis was implemented to assess the correlation between C0 and clinical, laboratory, pharmacological, and lifestyle factors. Fifteen females and seven males with a median age of 12.8 years (ranging between 4.7 and 17.2) were included. The median CBD dose was 8.8 mg/kg/day (ranging between 2.6 and 22.5), and the CBD C0 median (range) was 48.2 ng/mL (3.5-366.3). The multivariate model showed a 109.6% increase in CBD C0 in patients with concomitant levothyroxine (ß = 0.74 ± 0.1649, p < 0.001), 56.8% with food (ß = 0.45 ± 0.1550, p < 0.01), and 116.0% after intake of a ketogenic diet (ß = 0.77 ± 0.3141, p < 0.05). All patients included were responders without evidence of an association between C0 and response status. In children with DEEs, systemic concentrations of CBD may be significantly increased when co-administered with levothyroxine, food, or a ketogenic diet.

RESUMO

Basal ganglia calcifications may be a radiological finding in approximately 20% of the general population. When they are associated with neuropsychiatric and motor symptoms in an idiopathic form, they are known as Fahr's disease. They are termed "Fahr's syndrome" when they are secondary to an identifiable and potentially treatable cause. In this report, we present the clinical case of a 69-year-old woman with the onset of subacute chorea, with no other associated symptoms, in whom extensive basal ganglia calcifications were found on neuroimaging, due to which metabolic disorders were subsequently ruled out. The objective is to contribute to the characterization of the potential motor manifestations which would give rise to clinical suspicion. Due to its low incidence and the little information on this condition in the region, we want to encourage documentation of other cases and the process for ruling out other differential diagnoses, in order to obtain more information on its actual epidemiology and signs and symptoms in Colombia. (Acta Med Colomb 2022; 48. DOI:https://doi.org/10.36104/amc.2023.2635).

RESUMO

Objetivo: Reportamos resultados sobre la efectividad, seguridad y tolerancia del cannabidiol como adyuvante terapéutico en pacientes pediátricos con encefalopatías epilépticas del desarrollo (EED) resistentes al tratamiento farmacológico y no farmacológico tras un seguimiento promedio de 20 meses. Métodos: Se realizó un estudio de cohorte prospectivo para evaluar la eficacia, la seguridad y la tolerancia del aceite de cannabis medicinal enriquecido con CBD añadido a los medicamentos anticonvulsivos estándar en niños con EED resistentes a los medicamentos atendidos en un único centro. Resultados: Entre octubre de 2018 y marzo de 2020, se incluyeron 59 pacientes. La edad media en el momento del inicio del protocolo fue de 10,5 años (rango, 2-17 años). La mediana de la duración del tratamiento fue de 20 meses (rango, 12-32). La mediana de edad en el momento de la primera convulsión fue de 8 meses (rango, 1 día - 10 años). Al final del seguimiento, el 78% de los niños tenía una disminución ≥ 50% en frecuencia de las crisis y el 47,5% tenía una disminución > 75%. Siete pacientes (11,9%) estaban libres de convulsiones. El número de crisis se redujo de una mediana de 305/mes a 90/mes, que supone una reducción media del 57% y una mediana del 71% (p < 0,0001). Los efectos adversos fueron en su mayoría leves o moderados. El CBD se interrumpió en 17 pacientes (28,8%) por falta de respuesta al tratamiento, aumento de la frecuencia de las convulsiones, intolerancia al fármaco o cumplimiento terapéutico insuficiente. Conclusión: En los niños con EED resistentes a los fármacos, el tratamiento a largo plazo del cannabis medicinal enriquecido con CBD como terapia adyuvante resultó ser seguro, bien tolerado y eficaz. Las reducciones sostenidas en la frecuencia de las convulsiones y la mejora de los aspectos de la vida diaria se observaron en comparación con nuestros preliminares (AU)

Objective: We report results on the effectiveness, safety, and tolerance of cannabidiol (CBD) as add-on therapy in children with developmental and epileptic encephalopathies (DEE) resistant to pharmacological and non-pharmacological treatment after a mean follow-up of 20 months. Methods: A prospective cohort study was conducted to evaluate the efficacy, safety, and tolerability of CBD-enriched medical cannabis oil added to standard antiseizure medications in children with drug-resistant DEEs seen at a single center. Results: Between October 2018 and March 2020, 59 patients were included. The median age at protocol initiation was 10.5 years (range, 2-17 years). Median treatment duration was 20 months (range, 12-32). The median age at the time of the first seizure was 8 months (range, 1 day - 10 years). At the end of follow-up, 78% of the children had a decrease ≥ 50% in seizure frequency and 47.5% had a decrease of > 75%. Seven patients (11.9%) were seizure free. The number of seizures was reduced from a median of 305/month to 90/month, accounting for a mean reduction of 57% and a median of 71% (p < 0.0001). Adverse effects were mostly mild or moderate. CBD was discontinued in 17 patients (28.8%) due to lack of response to treatment, increased seizure frequency, drug intolerance, or poor compliance. Conclusion: In children with drug-resistant DEE, long-term treatment with CBD-enriched medicinal cannabis as add-on therapy proved to be safe, well tolerated, and effective. Sustained reductions in seizure frequency and improvement in aspects of daily living were observed compared to our preliminary results (AU)

Assuntos

RESUMO

The CYFIP2 protein (cytoplasmic FMR1-interacting protein 2) is part of the WAVE regulatory complex (WRC). CYFIP2 was recently correlated to neurological disorders by the association of the R87C variant with early infantile epileptic encephalopathy (EIEE) patients. In this set of syndromes, the epileptic spasms and seizures since early childhood lead to impaired neurological development in children. Inside the WRC, the variant residue is at the CYFIP2 and WAVE1 protein interface. Thus, the hypothesis is that the R87C modification weakens this interaction, allowing the WRC complex's constant activation. This work aimed to investigate the impacts of the mutation on the structure of the WRC complex through molecular dynamics simulation. For that, we constructed WRC models containing WAVE1-NCKAP1 proteins complexed with WT or R87C CYFIP2. Our simulations showed a flexibilization of the loop comprising residues 80-110 due to the loss of contacts between internal residues in the R87C CYFIP2 as well as the key role of residues R/C87, E624, and E689 in structural modification. These data could explain the mechanism by which the mutation impairs the stability and proper regulation of the WRC.

Assuntos

RESUMO

Background: Previous reported neurologic sequelae associated with SARS-CoV-2 infection have mainly been confined to hospital-based patients in which viral detection was restricted to nasal/throat swabs or to IgM/IgG peripheral blood serology. Here we describe seven cases from Brazil of outpatients with previous mild or moderate COVID-19 who developed subacute cognitive disturbances. Methods: From June 1 to August 15, 2020, seven individuals 18 to 60 years old, with confirmed mild/moderate COVID-19 and findings consistent with encephalopathy who were observed >7 days after respiratory symptom initiation, were screened for cognitive dysfunction. Paired sera and CSF were tested for SARS-CoV-2 (IgA, IgG ELISA, and RT-PCR). Serum and intrathecal antibody dynamics were evaluated with oligoclonal bands and IgG index. Cognitive dysfunction was assessed by the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and the Clock Drawing Test (CDT). Results: All but one of our patients were female, and the mean age was 42.6 years. Neurologic symptoms were first reported a median of 16 days (IQR 15-33) after initial COVID-19 symptoms. All patients had headache and altered behavior. Cognitive dysfunction was observed mainly in phonemic verbal fluency (MoCA) with a median of six words/min (IQR 5.25-10.75) and altered visuospatial construction with a median of four points (IQR 4-9) (CDT). CSF pleocytosis was not detected, and only one patient was positive for SARS-Co Conclusions: A subacute cognitive syndrome suggestive of SARS-CoV-2-initiated damage to cortico-subcortical associative pathways that could not be attributed solely to inflammation and hypoxia was present in seven individuals with mild/moderate COVID-19.

RESUMO

RESUMEN Introducción: Síndrome de encefalopatía posterior reversible PRES (también conocido como síndrome de leucoencefalopatía posterior reversible) se presenta con síntomas de inicio rápido como cefalea, convulsiones, alteración de la conciencia y alteración visual. A menudo, pero de ninguna manera siempre, se asocia con la hipertensión aguda. Metodología: Estudio de tipo revisión sistemática de la literatura. Se realizó una revisión sistemática de la literatura en las bases de datos PubMed/MEDLINE, LILACS y CICCO utilizando la sintaxis "Posterior reversible encephalopathy syndrome AND treatment". Los límites de búsqueda fueron publicaciones hechas en los últimos cinco años (2013-2020). Resultados: Se evaluaron 235 textos completos de los cuales finalmente se seleccionaron seis, esto teniendo en cuenta que los demás artículos no mencionaban de forma explícita el tratamiento, o eran redundantes con respecto a otros ya incluidos, teniendo en cuenta que el PRES tiene un manejo sintomático más que un tratamiento específico. Discusión: Síndrome de Encefalopatía Posterior Reversible (PRES) no tiene un tratamiento específico, sino más bien tiene un tratamiento sintomático lo que hace fundamental conocer las causas subyacentes al PRES ya que esa es la terapéutica a seguir, brindar el mejor tratamiento para lo que está causando este síndrome, de allí la importancia de conocer a fondo la etiología.

ABSTRACT Introduction: Posterior reversible encephalopathy syndrome PRES (also known as posterior reversible leukoencephalopathy syndrome) presents with rapid-onset symptoms such as headache, seizures, altered consciousness, and visual impairment. Often, but by no means always, it is associated with acute hypertension. Methods: Systematic literature review type study. A systematic review of the literature was carried out in the PubMed / MEDLINE, LILACS and CICCO databases using the syntax "Posterior reversible encephalopathy syndrome AND treatment". The search limits were publications made in the last five years (2013-2020). Results: 235 full texts were evaluated, of which six were finally selected, taking into account that the other articles did not explicitly mention the treatment, or were redundant with respect to others already included, taking into account that the PRES has symptomatic rather than specific treatment. Discussion: Posterior Reversible Encephalopathy Syndrome (PRES) does not have a specific treatment, but rather has a symptomatic treatment, which makes it essential to know the underlying causes of PRES since that is the therapy to follow, to provide the best treatment for what is causing this syndrome, hence the importance of fully understanding the etiology.

RESUMO

Genetic epidemiology studies have shown that most epilepsies involve some genetic cause. In addition, twin studies have helped strengthen the hypothesis that in most patients with epilepsy, a complex inheritance is involved. More recently, with the development of high-density single-nucleotide polymorphism (SNP) microarrays and next-generation sequencing (NGS) technologies, the discovery of genes related to the epilepsies has accelerated tremendously. Especially, the use of whole exome sequencing (WES) has had a considerable impact on the identification of rare genetic variants with large effect sizes, including inherited or de novo mutations in severe forms of childhood epilepsies. The identification of pathogenic variants in patients with these childhood epilepsies provides many benefits for patients and families, such as the confirmation of the genetic nature of the diseases. This process will allow for better genetic counseling, more accurate therapy decisions, and a significant positive emotional impact. However, to study the genetic component of the more common forms of epilepsy, the use of high-density SNP arrays in genome-wide association studies (GWAS) seems to be the strategy of choice. As such, researchers can identify loci containing genetic variants associated with the common forms of epilepsy. The knowledge generated over the past two decades about the effects of the mutations that cause the monogenic epilepsy is tremendous; however, the scientific community is just starting to apply this information in order to generate better target treatments.

Assuntos

RESUMO

Animal prion diseases are a group of neurodegenerative, transmissible, and fatal disorders that affect several animal species. The causative agent, prion, is a misfolded isoform of normal cellular prion protein, which is found in cells with higher concentration in the central nervous system. This review explored the sources of infection and different natural transmission routes of animal prion diseases in susceptible populations. Chronic wasting disease in cervids and scrapie in small ruminants are prion diseases capable of maintaining themselves in susceptible populations through horizontal and vertical transmission. The other prion animal diseases can only be transmitted through food contaminated with prions. Bovine spongiform encephalopathy (BSE) is the only animal prion disease considered zoonotic. However, due to its inability to transmit within a population, it could be controlled. The emergence of atypical cases of scrapie and BSE, even the recent report of prion disease in camels, demonstrates the importance of understanding the transmission routes of prion diseases to take measures to control them and to assess the risks to human and animal health.

Assuntos

RESUMO

Creutzfeldt and Jakob's disease (CJD) has its initial milestone in the publication issued 100 years ago that precipitated its better clinical-pathological and etiological understanding. Now, it is established that it belongs to the group of the prion diseases or transmissible spongiform encephalopathies family. CJD is itself divided into several types, the most common being sporadic that is further subdivided according to the anatomoclinical expression, but mainly due to its aetiology regarding prionic protein or genotype.

A doença de Creutzfeldt e Jakob (CJD) tem seu marco inicial na publicação emitida há 100 anos que precipitou seu melhor entendimento clínico- patológico e etiológico. Agora, está estabelecido que pertence ao grupo da família das doenças de príons ou encefalopatias espongiformes transmissíveis. A própria CJD se divide em vários tipos, sendo o mais comum o esporádico que também se subdivide de acordo com a expressão anatomoclínica, mas principalmente devido à sua etiologia em relação à proteína priônica ou genótipo.

Assuntos

RESUMO

OBJECTIVE: The aim of this study was to perform a molecular characterization of 17 Argentinean pediatric patients with diagnosis of having epileptic encephalopathies (EEs) of the first year of life without known etiology, applying next-generation sequencing (NGS). METHODS: We included 17 patients with EE with age of onset under 12 months without known etiology after ruling out structural abnormalities, metabolic disorders, and large chromosomal abnormalities. They presented with the following clinical phenotypes: Dravet syndrome (DS; n: 7), epilepsy of infancy with migrating focal seizures (EIMFS; n: 3), West syndrome (WS; n: 2), and undetermined epileptic encephalopathy (UEE; n: 5). Neurologic examinations, seizure semiology, brain magnetic resonance imaging, and standard electroencephalography (EEG) or video-EEG studies were performed in all cases. Using a custom amplicon strategy, we designed an NGS panel to study 47 genes associated with EEs. RESULTS: Pathogenic variants were detected in 8 cases (47%), including seven novel pathogenic variants and one previously reported as being pathogenic. The pathogenic variants were identified in 6 patients with DS (SCN1A gene), one with EIMFS (SCN2A gene), and one with UEE (SLC2A1 gene). Nonrelevant variants were identified in the patients with WS. CONCLUSION: We demonstrated the feasibility of an NGS-gene panel approach for the analysis of patients with EE in our setting. A genetic diagnosis was achieved in nearly 50% of patients, 87% of them presenting with nonpreviously reported variants. The early identification of the underlying causative genetic alteration will be a valuable tool for providing prognostic information and genetic counselling and also to improve therapeutic decisions in Argentinean patients.

Assuntos

RESUMO

ABSTRACT Background: Generalized periodic discharges (GPDs) are rare patterns that can be found in long-term electroencephalographic monitoring in critical patients. These patterns have been correlated with non-seizure crisis and non-convulsive status epilepticus, associated with poor prognosis. Objective: To compare the outcome between patients who developed GPDs and patients with other abnormalities in long-term electroencephalographic monitoring. Methods: A retrospective study was performed by analyzing the medical records of 112 patients over 18 years who developed GPDs during long-term electroencephalographic monitoring (12‒16 hours of monitoring) in the intensive care unit of a general hospital, compared with a group that had only nonspecific abnormalities in the monitoring. Results: Age and cardiorespiratory arrest (CA) were risk factors for death - OR 1.04 (95% CI 1,02 - 1,07) and p<0.001; OR 3.00 (95% CI 1,01 - 8,92) and p=0.046, respectively. It was not possible to evaluate if GPDs alone were associated with an unfavorable outcome or would be a bias for the development of CA in these patients. However, of the six isolated GPDs cases, 2/3 evolved to death, showing a tendency to worse prognosis. A significant difference (p=0.031) was observed for a worse outcome when comparing the group of 28 patients who presented GPD or CA with the other group which did not present any of these variables; of these 28 patients, 20 (71.4%) died. Conclusions: The presence of post-CA GPDs was associated with worse prognosis, but it was not clear whether these patterns are independent factors of an unfavorable evolution.

RESUMO Introdução: As descargas periódicas generalizadas (DPG) são padrões raros que podem ser encontrados durante monitorização eletroencefalográfica prolongada (MEP) em pacientes críticos. Esses padrões têm sido correlacionados com crises não convulsivas e estado de mal epiléptico não convulsivo, associados a um pior prognóstico. Objetivo: Comparar o desfecho entre pacientes que desenvolveram DPG e pacientes com anormalidades inespecíficas na MEP. Métodos: Foi realizado um estudo retrospectivo através da análise dos prontuários de 112 pacientes acima de 18 anos que desenvolveram DPG durante MEP (de 12‒16 horas de monitorização) na unidade de terapia intensiva de um hospital geral, comparando com um grupo que apresentou apenas anormalidades inespecíficas na MEP. Resultados: As variáveis idade e parada cardiorrespiratória (PCR) se mostraram como fatores de risco estatisticamente significativos para óbito - OR 1,04 (IC 95% 1,02 - 1,07) e p<0,001; OR 3,00 (IC 95% 1,01 - 8,92) e p=0,046, respectivamente. Não foi possível avaliar se DPG isoladamente se associaram a um desfecho desfavorável ou seriam um viés para o desenvolvimento de PCR nesses pacientes. Porém, dos seis casos de DPG isoladas, 2/3 evoluíram para óbito, o que revela uma tendência a pior prognóstico. Foi observada diferença significativa (p=0,031) para pior desfecho ao comparar o grupo de 28 pacientes que apresentou DPG ou PCR com o outro grupo que não apresentou nenhuma dessas variáveis, sendo que desses 28 pacientes, 20 (71,4%) foram a óbito. Conclusões: A presença de DPG pós-PCR está associada a pior prognóstico, porém não ficou claro se esses padrões são fatores independentes de evolução desfavorável.

Assuntos

RESUMO

OBJECTIVE: Here, we present a multicenter series of patients with developmental and epileptic encephalopathies (DEE) and related electroclinical patterns (REP) other than Lennox-Gastaut syndrome (LGS) who were treated with rufinamide as add-on therapy. METHODS: Medical records of 34 patients with DEE and REP other than LGS treated with add-on rufinamide seen at four pediatric neurology centers in Argentina between May 2014 and March 2019 were retrospectively analyzed. RESULTS: We evaluated 34 patients (18 males, 16 females), aged between 2 and 15 years with a mean and median age of 6 and 8 years, respectively. The children had different types of childhood-onset refractory DEE and REP other than LGS and were treated with rufinamide for a mean period of 20 months (range, 12-60 months). Twenty-two of 34 patients (64.5%) who received rufinamide as add-on therapy had a greater than 50% decrease in seizures, and two patients (5.8%) became seizure-free. Four patients (11.7%) had a 25-50% seizure reduction, while seizure frequency remained unchanged in four others (11.7%) and increased in two patients (5.8%). The final mean dosage of rufinamide was 31.5 ±â€¯15.5 mg/kg per day (range, 19-75.4 mg/kg) if combined with valproic acid and of 35.4 ±â€¯11.5 mg/kg per day (range, 8-60.5 mg/kg) without valproic acid. Adverse effects were recorded in nine patients (26.4%). A seizure increase was reported in two of 24 patients (7.3%). CONCLUSION: Rufinamide may be used as a treatment option in DEE and REP other than LGS.

Assuntos

RESUMO

In this article, we describe the importance of coexisting medical problems in the diagnosis of autism spectrum disorder (ASD). It is worth noting the role of pediatricians as health care providers trained to assess, test, diagnose, and treat such conditions during childhood. The population diagnosed with ASD is systemically vulnerable. ASD is the name given to a group of symptoms resulting from a systemic, dynamic, chronic encephalopathy according to the model proposed by Martha Herbert, M.D. (Harvard, USA). Based on this model, we may describe the circumstances of patients' families who, in Argentina, are unable to find answers on the coexisting medical problems in the diagnosis of ASD according to the psychoanalytic, genetic, and neurodiversity models. It is necessary to review current models in the setting of humanism in medicine because, so far, results have not been as expected.

Este artículo presenta la importancia de los problemas médicos concomitantes al diagnóstico del trastorno del espectro autista (TEA). Se resalta el rol del pediatra como el profesional médico preparado para evaluar, testear, diagnosticar y tratar estos problemas en la niñez. La población con diagnóstico de TEA es vulnerable sistémicamente. TEA es el nombre dado a una sintomatología emergente de una encefalopatía crónica, dinámica y sistémica según el modelo de la doctora Martha Herbert (Harvard, EE. UU.). Basados en este, se plantea la situación de las familias de los pacientes, en la Argentina, que no encuentran respuestas sobre los problemas médicos concomitantes al diagnóstico del TEA con los modelos: psicoanalítico, genético y de las neurodiversidades. Se establece la necesidad de revisar los modelos vigentes, en el marco del humanismo en medicina, debido a que los resultados no son los esperados.

Assuntos

RESUMO

Dyke-Davidoff-Masson Syndrome is a syndrome associated with refractory epilepsy. The Chiari II malformation is a complex congenital malformation of the brain. The authors report a case of a 15 years-old adolescent presenting Dyke-Davidoff-Masson syndrome and Chiari type II malformation association. This case demonstrates an unusual association in neuroimaging tests that indicates the need to evaluate associated diseases, such as myelomeningocele, corpus callosum dysgenesis and syringohydromyelia.

A Síndrome de Dyke-Davidoff-Masson é uma síndrome associada à epilepsia refratária. A malformação de Chiari II é uma malformação congênita complexa do cérebro. Os autores relatam um caso de uma adolescente de 15 anos apresentando a síndrome de Dyke-Davidoff-Masson associada à malformação de Chiari tipo II. Este caso demonstra uma associação incomum nos exames de neuroimagem que indica a necessidade de avaliar doenças associadas, como mielomeningocele, disgenesia do corpo caloso e a siringohidromielia.

Assuntos

RESUMO

São descritas doenças do sistema nervoso central (SNC) em cães diagnosticadas no sertão da Paraíba. Os registros de necropsia de 1.205 cães foram revisados. Em 354 casos (29,38%) foram registrados história clínica de alterações do sistema nervoso. Duzentos e noventa e seis casos tiveram diagnóstico definitivo e 58 foram inconclusivos. As doenças infecciosas foram observadas em 59,60% (211/354) de casos que representam a principal causa de distúrbios neurológicos; 53% dos casos (186/354) foram representadas por doenças virais; 3,11% (11/354) foram de etiologia parasitária, 2,54% (9/354) foram causadas por bactérias e 1,41% (5/354) por fungos. Os agentes físicos representaram a segunda causa mais importante de transtornos do SNC com 9,89% (35/354) e os tumores a terceira causa com 5,93% (21/354). Outras alterações pouco frequentes foram alterações metabólicas secundárias a insuficiência hepática ou renal, representando 2,54% (9/354). Casos raros de hidrocefalia congênita foram observados, 1,41% (5/354). Os casos de manifestações neurológicas associadas a alterações vasculares, degenerativas e inflamatórias não infecciosas, muitas das quais uma causa específica não foi estabelecida representaram 4,24% (15/354); Estavam dentro das seguintes categorias de doenças: Infartos isquêmicos e hemorrágicos (6/15), necrose vascular fibrinoide (5/15), doença do disco intervertebral (2/15), meningoencefalite granulomatosa (1/15) e granuloma de colesterol (1/15). Os distúrbios do sistema nervoso central representam uma importante causa de morte ou eutanásia em cães na região semiárida da Paraíba. Os sinais clínicos variaram de acordo com o agente envolvido, localização e distribuição das lesões. O conhecimento dos principais agentes que pode afetar o SNC canino é importante ao fazer uma lista de diagnóstico diferencial.(AU)

Central nervous system (CNS) diseases in dogs diagnosed in the backlands of Paraiba are described. The necropsy records of 1,205 of dogs were reviewed. In 354 cases (29.38%) a history of clinical alterations of the nervous system were recorded. Two hundred and ninety six cases had a definitive diagnosis and 58 were inconclusive. Infectious diseases were observed in 59.60% (211/354) of cases representing the main cause of neurological disorders; 53% of the cases (186/354) were represented by viral diseases; 3.11% (11/354) were of parasitic etiology, 2.54% (9/354) were caused by bacteria and 1.41% (5/354) by fungi. Physical agents represented the second most important cause of CNS disorders with 9.89% (35/354) and tumors third cause with 5.93% (21/354). Other uncommon observed disorders were metabolic changes secondary to liver or kidney failure, accounting for 2.54% (9/354). Rare cases of congenital hydrocephalus were observed, 1.41% (5/354). The cases of neurological manifestations associated with vascular, degenerative and inflammatory noninfectious lesions, for many of which were specific cause was not established accounted for 4.24% (15/354); they were within the following disease categories: ischemic and hemorrhagic infarcts (6/15), vasculitis fibrinoide necrosis (5/15), intervertebral disc disease (2/15), granulomatous meningoencephalitis (1/15) and cholesterol granuloma (1/15). The central nervous system disorders represent an important cause of death or reason for euthanasia in dogs in the semiarid region of Paraiba. Clinical signs vary according to the agent involved, and the location and distribution of the lesions. The knowledge of the main agents that can affect the canine CNS it is important when making a list of differential diagnosis.(AU)

Assuntos

RESUMO

São descritas doenças do sistema nervoso central (SNC) em cães diagnosticadas no sertão da Paraíba. Os registros de necropsia de 1.205 cães foram revisados. Em 354 casos (29,38%) foram registrados história clínica de alterações do sistema nervoso. Duzentos e noventa e seis casos tiveram diagnóstico definitivo e 58 foram inconclusivos. As doenças infecciosas foram observadas em 59,60% (211/354) de casos que representam a principal causa de distúrbios neurológicos; 53% dos casos (186/354) foram representadas por doenças virais; 3,11% (11/354) foram de etiologia parasitária, 2,54% (9/354) foram causadas por bactérias e 1,41% (5/354) por fungos. Os agentes físicos representaram a segunda causa mais importante de transtornos do SNC com 9,89% (35/354) e os tumores a terceira causa com 5,93% (21/354). Outras alterações pouco frequentes foram alterações metabólicas secundárias a insuficiência hepática ou renal, representando 2,54% (9/354). Casos raros de hidrocefalia congênita foram observados, 1,41% (5/354). Os casos de manifestações neurológicas associadas a alterações vasculares, degenerativas e inflamatórias não infecciosas, muitas das quais uma causa específica não foi estabelecida representaram 4,24% (15/354); Estavam dentro das seguintes categorias de doenças: Infartos isquêmicos e hemorrágicos (6/15), necrose vascular fibrinoide (5/15), doença do disco intervertebral (2/15), meningoencefalite granulomatosa (1/15) e granuloma de colesterol (1/15). Os distúrbios do sistema nervoso central representam uma importante causa de morte ou eutanásia em cães na região semiárida da Paraíba. Os sinais clínicos variaram de acordo com o agente envolvido, localização e distribuição das lesões. O conhecimento dos principais agentes que pode afetar o SNC canino é importante ao fazer uma lista de diagnóstico diferencial.(AU)

Central nervous system (CNS) diseases in dogs diagnosed in the backlands of Paraiba are described. The necropsy records of 1,205 of dogs were reviewed. In 354 cases (29.38%) a history of clinical alterations of the nervous system were recorded. Two hundred and ninety six cases had a definitive diagnosis and 58 were inconclusive. Infectious diseases were observed in 59.60% (211/354) of cases representing the main cause of neurological disorders; 53% of the cases (186/354) were represented by viral diseases; 3.11% (11/354) were of parasitic etiology, 2.54% (9/354) were caused by bacteria and 1.41% (5/354) by fungi. Physical agents represented the second most important cause of CNS disorders with 9.89% (35/354) and tumors third cause with 5.93% (21/354). Other uncommon observed disorders were metabolic changes secondary to liver or kidney failure, accounting for 2.54% (9/354). Rare cases of congenital hydrocephalus were observed, 1.41% (5/354). The cases of neurological manifestations associated with vascular, degenerative and inflammatory noninfectious lesions, for many of which were specific cause was not established accounted for 4.24% (15/354); they were within the following disease categories: ischemic and hemorrhagic infarcts (6/15), vasculitis fibrinoide necrosis (5/15), intervertebral disc disease (2/15), granulomatous meningoencephalitis (1/15) and cholesterol granuloma (1/15). The central nervous system disorders represent an important cause of death or reason for euthanasia in dogs in the semiarid region of Paraiba. Clinical signs vary according to the agent involved, and the location and distribution of the lesions. The knowledge of the main agents that can affect the canine CNS it is important when making a list of differential diagnosis.(AU)

Assuntos